New pill tested for Tough-to-Treat blood cancer
NCT ID NCT05141682
Summary
This study is testing an oral drug called CC-486 for adults with a rare blood cancer called T-cell large granular lymphocytic leukemia (T-LGLL) that has come back or hasn't responded to previous treatment. The first part of the trial aims to find the safest and most effective dose. The second part will see how well the drug works to control the cancer and improve patients' blood counts and symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.